Core Viewpoint - The company reported a significant decline in revenue and net profit for the six months ending June 30, 2025, primarily due to changes in industry conditions and adjustments in marketing strategies [1] Financial Performance - The company achieved revenue of 319 million yuan, representing a year-on-year decrease of 39.14% [1] - Net profit was recorded at 83.67 million yuan, down 37.65% compared to the previous year [1] - Basic loss per share was reported at 11.32 cents [1] Market Conditions - The decline in revenue is attributed to changes in the industry landscape during the first half of 2025 [1] - Adjustments in the company's product marketing strategies led to a reduction in purchases by customers and distributors in the first half of 2025 [1]

Financial Performance - The group's revenue decreased by approximately RMB 205.3 million or 39.1% to about RMB 319.2 million for the six months ended June 30, 2025, compared to the same period in 2024[3]. - Gross profit fell by approximately RMB 145.5 million or 37.1% to about RMB 246.3 million for the same period[3]. - Profit before tax decreased by approximately RMB 69.7 million or 35.6% to about RMB 125.9 million[3]. - Profit attributable to equity holders of the company decreased by approximately RMB 50.5 million or 37.6% to about RMB 83.7 million[3]. - Total comprehensive income for the period was RMB 80.1 million, down from RMB 135.6 million in the previous year[5]. - The group's profit before tax for the six months ended June 30, 2025, was RMB 72,926,000, a decrease of 45% compared to RMB 132,687,000 for the same period in 2024[13]. - Net profit for the six months ended June 30, 2025, was approximately RMB 83.7 million, a decrease of about RMB 50.5 million or 37.6% from RMB 134.2 million in the same period of 2024, attributed to a decline in product sales[69]. Dividend and Shareholder Returns - The board of directors did not recommend the declaration of any interim dividend for the six months ended June 30, 2025[3]. - The group declared a final dividend of HKD 0.5 per ordinary share for the six months ended June 30, 2025, down from HKD 0.6 in 2024, totaling RMB 338,663,000 compared to RMB 403,765,000[18]. - The company did not declare any interim dividends for the six months ended June 30, 2025, consistent with the previous year[18]. - The board does not recommend declaring any interim dividend for the six months ended June 30, 2025[87]. Assets and Liabilities - Cash and cash equivalents decreased to RMB 1,042.4 million from RMB 1,130.6 million as of December 31, 2024[6]. - Trade receivables decreased significantly to RMB 243.2 million from RMB 420.6 million[6]. - The total assets less current liabilities amounted to RMB 1,258.4 million, down from RMB 1,550.7 million[7]. - The company's equity attributable to equity holders decreased to RMB 1,207.8 million from RMB 1,466.3 million[7]. - As of June 30, 2025, the company's current assets net value was approximately RMB 748.8 million, down from RMB 1,055.7 million as of December 31, 2024[70]. - Total interest-bearing bank loans and other borrowings increased to approximately RMB 684.0 million, up about RMB 257.1 million or 60.2% from RMB 426.9 million at the end of 2024[71]. - The debt-to-equity ratio increased from approximately 29.1% as of December 31, 2024, to about 56.6% as of June 30, 2025[73]. Revenue Sources - The group's flagship product, Jin Sangzi throat lozenges (OTC), accounted for approximately 90.6% of total revenue for the six months ended June 30, 2025[38]. - Revenue from the sales of Jin Sangzi throat lozenges (OTC) was approximately RMB 289.1 million, down by RMB 189.3 million or 39.6% from RMB 478.4 million in the previous year[55]. - The Jin Sangzi throat treasure series products contributed about 8.9% to total revenue for the same period, with new export markets including South Korea and Peru[40]. - Other products, including Ginkgo biloba tablets and the new Jin Sangzi intestinal treasure, represented about 0.5% of total revenue[41]. Research and Development - The group has developed 35 new products since 1994, obtaining production licenses for 8 pharmaceutical products, 21 food products, 1 health food product, and 1 medical device[42]. - The group is collaborating with Beijing Agricultural University on the development of a new composite probiotic lozenge, which has obtained six patents[41]. - The company launched the Jin Sang Zi compound probiotic lozenges in collaboration with Beijing Agricultural University, utilizing proprietary strains and securing six patents[43]. - By 2025, the Jin Sang Zi compound probiotic series will be upgraded to include nine patented strains, significantly enhancing its efficacy in areas such as immune regulation and blood sugar control[43]. - The group has a strong focus on R&D, collaborating with hospitals and research institutions to enhance product development[42]. Market Position and Strategy - The company aims to strengthen its brand recognition and image in China through increased advertising and targeted marketing strategies[53]. - The company aims to strengthen its market position in the throat lozenge market and expand its market share in the pharmaceutical and food sectors in the second half of 2025[82]. - The company has successfully exported products to over 60 countries and regions, with new markets including South Korea and Peru added in early 2025[46]. - The company has established a flagship store on Tmall, introducing various new products including six flavors of Jin Sang Zi throat lozenges[48]. - The company has signed promotional agreements with 11 promoters to enhance local market penetration and feedback[49]. Operational Updates - The company plans to enhance its production capacity by constructing a new production base in Liuzhou, Guangxi, covering an area of approximately 60,000 square meters, which includes a research and development center and automated production lines[53]. - The company has selected a 48-acre site for the second phase of the Jin Sangzi new base, which is expected to have a built-up area of approximately 50,000 square meters, focusing on the development of health products[54]. - The construction of the food production plant and R&D center has completed above-ground construction and has commenced internal construction as of June 30, 2025[85]. - The total amount allocated for the construction of the food production plant and R&D center is HKD 177.4 million, with an unutilized balance of HKD 151.4 million as of June 30, 2025[84]. - The company has reallocated approximately HKD 37.997 million originally intended for establishing a Chinese herbal processing base to the construction of the food production plant and R&D center[84]. Governance and Compliance - The audit committee has reviewed the unaudited interim consolidated financial statements for the six months ended June 30, 2025, and found the existing risk management and internal control systems to be effective and adequate[92]. - The company has adopted a corporate governance code to ensure high standards of corporate governance and protect shareholder interests[88].

Group 1 - The company, Jin Sang Zi (06896.HK), announced that its board meeting will be held on August 28, 2025, to review and approve the interim results for the six months ending June 30, 2025 [1] - The meeting will also consider the declaration and distribution of an interim dividend, if any [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容 而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 GOLDEN THROAT HOLDINGS GROUP COMPANY LIMITED 金嗓子控股集團有限公司（「本公司」）董事會（「董事會」）謹此宣佈，董事會會議將於2025 年8月28日（星期四）舉行，藉以（其中包括）審議及批准本公司及其附屬公司截至2025年6 月30日止六個月之中期業績及其發佈，並考慮宣派及派發中期股息（如有）。 承董事會命 金嗓子控股集團有限公司 主席 江佩珍 中國廣西 2025年8月18日 6896 董事會會議通告 本公告乃根據香港聯合交易所有限公司證券上市規則第13.43條而作出。 於本公告日期，董事會成員包括非執行董事江佩珍女士；執行董事曾勇先生、黃建平先 生、曾克雄先生及何錦強先生；及獨立非執行董事李驊先生、朱頡榕先生、程益群先生 及覃解生先生。 ...

Group 1: Hong Kong Stock Market Performance - Zhengda Enterprise International (03839) surged over 20% after reporting a revenue of approximately $323 million, a year-on-year increase of 199.44%, and a net profit attributable to shareholders of $17.046 million, up 768.36% [2] - Zhenjiu Lidu (06979) rose over 11% as research indicated that the liquor industry is moving towards a performance bottom, with expectations for a trend reversal in stock prices ahead of demand recovery [2] - Lithium stocks fell, with Tianqi Lithium (09696) down over 7.5% and Ganfeng Lithium (01772) down over 5.7%, due to anticipated long-term production halts affecting domestic lithium carbonate output by nearly 12% [2] - China General Nuclear Power (01816) increased over 3% as it plans to commission multiple nuclear units between 2025 and 2030, with expectations of a long-term price rebound in the Guangdong region [2] Group 2: Company Earnings Reports - Hillstone Technology (01478) reported a revenue of 8.832 billion RMB for the first half of the year, a year-on-year increase of 15.1%, and a net profit of 308 million RMB, up 167.6% [4] - Jinsongzi (06896) fell nearly 20% after issuing a profit warning, expecting a profit decrease of about 37% compared to the same period in 2024 [4] - Jinke Services (09666) rose over 7% after announcing an expected net profit of approximately 0 to 100 million RMB for the six months ending June 30, 2025, compared to a net loss of 194.4 million RMB in the same period last year [4] - Jingtai Holdings (02228) increased nearly 5%, forecasting a comprehensive income of no less than 500 million RMB for the first half of 2025, a year-on-year increase of at least 387% [4] Group 3: U.S. Stock Market Highlights - AMD (AMD.US) fell 0.28% after confirming it received preliminary approval for AI chip exports to China [6] - TSMC (TSM.US) rose 0.11% with July sales reaching approximately $10.806 billion, a year-on-year increase of 25.8% [6] - Micron Technology (MU.US) increased by 4.06% after raising its revenue guidance for Q4 2025 to $11.1 billion to $11.3 billion, citing improved DRAM pricing conditions [6] - Intel (INTC.US) rose 3.51% amid news of CEO Pat Gelsinger's planned discussions with the White House [7] Group 4: Emerging Companies and Innovations - Tesla (TSLA.US) rose 2.85% after applying for a power supply license in the UK, aiming to compete with local energy giants [8] - Bilibili (BILI.US) increased by 1.67%, with a report highlighting that 70% of China's Z+ generation are users of the platform, indicating strong user engagement [8] - XPeng Motors (XPEV.US) continued to rise by 5.84% as its new extended-range model entered the new vehicle announcement list, indicating an upcoming launch [8]

Core Viewpoint - The company Jin Sang Zi (06896.HK) has issued a profit warning, indicating a significant decline in profit for the upcoming financial period [1] Company Summary - The company expects a year-on-year profit decrease of approximately 37% for the six months ending June 30, 2025 [1] - The decline in profit is attributed to changes in industry conditions and adjustments in the company's product marketing strategy [1] - As a result of these changes, customer distributors have reduced their purchases, leading to a decrease in both sales and profit [1]

Group 1 - The company, Jin Sang Zi (6896.HK), issued a profit warning, leading to a stock price drop of over 24%, reaching a new low of 3.75 HKD since April 25 [2] - The company expects a year-on-year profit decrease of approximately 37% for the first half of the year ending June, primarily due to changes in industry conditions and adjustments in product marketing strategies [2] - The reduction in customer and distributor purchases has resulted in a decline in both sales and profits for the company [2] Group 2 - The trading volume significantly increased, with nearly 22 million HKD transacted, indicating heightened market activity [2]

Group 1 - The company Jin Sangzi (06896) issued a profit warning, resulting in a decline of over 23% in its stock price, trading at 3.79 HKD with a transaction volume of 5.3713 million HKD [1] - The company expects a profit decrease of approximately 37% for the six months ending June 30, 2025, compared to the same period in 2024 [1] - The profit decline is attributed to changes in industry conditions and adjustments in the company's product marketing strategy, leading to reduced purchases from customers and distributors in the first half of 2025, which negatively impacted sales and profits [1]

Group 1 - The company's stock price dropped by 15.15% on August 12, reaching 4.2 HKD per share with a trading volume of 4.268 million HKD [1] - The company, Jin Sang Zi Holdings Limited, specializes in the pharmaceutical and food health industry, producing over 60 products including throat lozenges and health candies, with an annual production capacity of 5 billion throat lozenges and an annual output value of 1 billion [1] - The company has several international certifications and its market presence spans over 20 countries and regions, including the US, Canada, EU, Russia, Australia, and Southeast Asia [1] Group 2 - As of the 2024 annual report, the company's total operating revenue was 1.185 billion RMB and net profit was 319 million RMB [2] - A forecast for the mid-2025 report indicates a projected profit decrease of 37% year-on-year [3]

Core Viewpoint - The company Jin Sang Zi (06896) issued a profit warning, leading to a significant drop of over 23% in its stock price, currently trading at 3.79 HKD with a trading volume of 5.3713 million HKD [1] Financial Performance - The company anticipates a profit decrease of approximately 37% for the six months ending June 30, 2025, compared to the same period in 2024 [1] - The decline in profit is attributed to changes in industry conditions and adjustments in the company's product marketing strategy [1] Sales and Marketing Impact - The adjustments in marketing strategy have resulted in reduced purchases from customers and distributors for the first half of 2025, leading to a decline in both sales and profit [1]